Seminars in Hematology
Volume 46, Issue 4 , Pages 325-327 , October 2009

The New Age of Iron: Evaluation and Management of Iron-Restricted Erythropoiesis

References 

  1. Brugnara C, Laufer MR, Friedman AJ, Bridges K, Platt O. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood. 1994;83:3100–3101
  2. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44:45–51
  3. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–4297
  4. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113:5277–5286
  5. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231–242
  6. Eschbach JW, Haley NR, Egrie JC, Adamson JW. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int. 1992;42:407–416
  7. Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol. 2007;35(Suppl 1):167–172
  8. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest. 2002;32(Suppl 1):70–78
  9. Crosby WH. The rationale for treating iron deficiency anemia. Arch Intern Med. 1984;144:471–472
  10. Bonnar J, Goldberg A, Smith JA. Do pregnant women take their iron?. Lancet. 1969;1:457–458
  11. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–1307
  12. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530–538
  13. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–46
  14. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: update 2006. Am J Kidney Dis. 2006;4:S1–S145
  15. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–147

PII: S0037-1963(09)00105-X

doi: 10.1053/j.seminhematol.2009.07.002

Seminars in Hematology
Volume 46, Issue 4 , Pages 325-327 , October 2009

Article Tools